Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:47:01.256Z.
Calculation as of: 2026-10-06T14:47:01.256Z.
Quote observation: 2026-10-06T14:45:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26a6c2e450689c32f4e4e5954cf906f309ed45562a8b136dc87c806878a45fac
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$5.94B
Operating Cash Flow Yield
2.22%
TTM Avg
1.51%
3Y Avg
3.26%
5Y Avg
5.50%
Market Cap
$5.82B
Operating Cash Flow Yield
N/A
TTM Avg
100.19%
3Y Avg
100.19%
5Y Avg
100.19%
Market Cap
$6.40B
Operating Cash Flow Yield
3.14%
TTM Avg
6.96%
3Y Avg
12.38%
5Y Avg
19.52%
Market Cap
$5.63B
Operating Cash Flow Yield
3.29%
TTM Avg
3.25%
3Y Avg
2.26%
5Y Avg
2.35%
Market Cap
$6.53B
Operating Cash Flow Yield
6.32%
TTM Avg
8.37%
3Y Avg
7.89%
5Y Avg
6.14%
Market Cap
$5.56B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.60B
Operating Cash Flow Yield
4.04%
TTM Avg
4.34%
3Y Avg
3.15%
5Y Avg
2.87%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.00B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 2.22% | 1.51% | 3.26% | 5.50% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.82B | N/A | 100.19% | 100.19% | 100.19% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.40B | 3.14% | 6.96% | 12.38% | 19.52% |
| CG Oncology Inc. (CGON)vs › | $5.70B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.63B | 3.29% | 3.25% | 2.26% | 2.35% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 6.32% | 8.37% | 7.89% | 6.14% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.56B | N/A | N/A | N/A | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.60B | 4.04% | 4.34% | 3.15% | 2.87% |
| Immunovant, Inc. (IMVT)vs › | $6.63B | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
